◆英語タイトル:Sonoma Pharmaceuticals Inc (OCLS) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME13919FSA
◆発行会社(調査会社):
GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Sonoma Pharmaceuticals Inc (Sonoma), formerly Oculus Innovative Sciences, is a pharmaceutical company that develops, manufactures and markets prescription and non-prescription products for the treatment of dermatological conditions and advanced tissue care. The company offers products for advanced wound management, nursing home and home healthcare, wound and skin care, among others. It offers women’s healthcare products, Microcyn skin and wound care products, Regenacyn advanced scar management hydrogel and animal healthcare, among others. Sonoma develops its products based on shelf-stable microcyn technology platform. The company sells its products through OTC stores. The company operates in the Netherlands and the US. Sonoma is headquartered in Woodstock, Georgia, the US.
Sonoma Pharmaceuticals Inc Key Recent Developments
Mar 31,2021: Sonoma Pharmaceuticals and EMC Pharma Announce an Exclusive Partnership to Expand Commercial Channels of the Microcyn®-based Rx Dermatology and Eye Care Products Nationwide
Mar 04,2021: Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences
Feb 16,2021: Sonoma Pharmaceuticals reports third quarter FY 2021 financial results
Jan 11,2021: Sonoma Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
Dec 10,2020: Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn technology-based Anti-Itch Over-the-Counter Products
This comprehensive SWOT profile of Sonoma Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Sonoma Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 – About the Company
Sonoma Pharmaceuticals Inc – Key Information
Sonoma Pharmaceuticals Inc – Overview
Sonoma Pharmaceuticals Inc – Key Employees
Sonoma Pharmaceuticals Inc – Key Employee Biographies
Sonoma Pharmaceuticals Inc – Key Operational Heads
Sonoma Pharmaceuticals Inc – Major Products and Services
Sonoma Pharmaceuticals Inc – History
Sonoma Pharmaceuticals Inc – Company Statement
Sonoma Pharmaceuticals Inc – Locations And Subsidiaries
Sonoma Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Sonoma Pharmaceuticals Inc – Business Description
Sonoma Pharmaceuticals Inc – Corporate Strategy
Sonoma Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Sonoma Pharmaceuticals Inc – Strengths
Sonoma Pharmaceuticals Inc – Weaknesses
Sonoma Pharmaceuticals Inc – Opportunities
Sonoma Pharmaceuticals Inc – Threats
Sonoma Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Performance Charts
Sonoma Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Appendix
Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Note*: Some sections may be missing if data is unavailable for the company
List of Tables
Sonoma Pharmaceuticals Inc, Key Information
Sonoma Pharmaceuticals Inc, Key Ratios
Sonoma Pharmaceuticals Inc, Share Data
Sonoma Pharmaceuticals Inc, Major Products and Services
Sonoma Pharmaceuticals Inc, History
Sonoma Pharmaceuticals Inc, Key Employees
Sonoma Pharmaceuticals Inc, Key Employee Biographies
Sonoma Pharmaceuticals Inc, Key Operational Heads
Sonoma Pharmaceuticals Inc, Other Locations
Sonoma Pharmaceuticals Inc, Subsidiaries
Sonoma Pharmaceuticals Inc, Key Competitors
Sonoma Pharmaceuticals Inc, SWOT Analysis
Sonoma Pharmaceuticals Inc, Ratios based on current share price
Sonoma Pharmaceuticals Inc, Annual Ratios
Sonoma Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios